HATs off to epigenetics
How AbbVie is expanding its reach in cancer epigenetics
Although the epigenetics field is heating up, most compounds on the market and in development are clustered around the same small set of targets. Now, a team led by AbbVie Inc. (NYSE:ABBV) has uncovered an inhibitor of two histone acetyltransferases, a class of epigenetic enzymes largely untouched by drug developers.
In a paper published in Nature last month,